United Therapeutics Corporation (UTHR)

NASDAQ: UTHR · Real-Time Price · USD

456.84

+3.56 (0.79%)

At close: Oct 7, 2025, 4:00 PM EDT

454.05

-2.79 (-0.61%)

After-hours: Oct 7, 2025, 7:58 PM EDT

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2013 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2013 - 2020
Tyvaso Revenue	1.79B	1.62B	Log In	Log In	Log In	Upgrade
Remodulin Revenue	535.70M	538.10M	Log In	Log In	Log In	Upgrade
Orenitram Revenue	465.60M	434.30M	Log In	Log In	Log In	Upgrade
Unituxin Revenue	245.20M	238.70M	Log In	Log In	Log In	Upgrade
Adcirca Revenue	24.20M	23.80M	Log In	Log In	Log In	Upgrade
Total Product Sales Revenue	3.06B	2.86B	Log In	Log In	Log In	Upgrade
Revenue (Other)	21.50M	22.10M	Log In	Log In	Log In	Upgrade
Revenue (Total)	3.08B	2.88B	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2013 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2013 - 2020
United States Revenue	2.93B	2.74B	Log In	Log In	Log In	Upgrade
Rest-of-World Revenue	145.40M	137.70M	Log In	Log In	Log In	Upgrade
Revenue (Total)	3.08B	2.88B	Log In	Log In	Log In	Upgrade

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2013 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2013 - 2020
Tyvaso Gross Profit	1.58B	1.44B	Log In	Log In	Log In	Upgrade
Remodulin Gross Profit	480.90M	490.70M	Log In	Log In	Log In	Upgrade
Orenitram Gross Profit	437.30M	405.90M	Log In	Log In	Log In	Upgrade
Unituxin Gross Profit	230.20M	224.30M	Log In	Log In	Log In	Upgrade
Adcirca Gross Profit	14.00M	13.70M	Log In	Log In	Log In	Upgrade
Total Product Sales Gross Profit	2.74B	2.57B	Log In	Log In	Log In	Upgrade
Gross Profit (Other)	-6.10M	-4.80M	Log In	Log In	Log In	Upgrade
Gross Profit (Total)	2.74B	2.57B	Log In	Log In	Log In	Upgrade

Updated Jul 30, 2025. Data Source: Fiscal.ai.